tbuckley/cabot-search huggingface dataset:
1356P Disease monitoring and TKI resistance mutations of EGFR mutation-positive NSCLC patients via circulating tumour DNA
Authors: C. Ju, J. Jiang, C. Woestmann, B. Hinzmann, S. Yaung, M. Thomas, C.P. Heussel, M. Kriegsmann, M. Meister, M. Schneider, F. Herth, T. Muley, B. Wehnl, J.F. Palma
Journal: Annals of Oncology (2020)
LBA23 Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361
Authors: A. Alva, T. Csőszi, M. Ozguroglu, N. Matsubara, L. Geczi, S.Y-S. Cheng, Y. Fradet, S. Oudard, C. Vulsteke, R. Morales Barrera, A. Fléchon, S. Gunduz, Y. Loriot, A. Rodriguez-Vida, R. Mamtani, E.Y. Yu, K. Nam, K. Imai, B.H. Moreno, T.B. Powles
Journal: Annals of Oncology (2020)
745P Patient-reported outcomes (PROs) from JAVELIN Bladder 100: Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC)
Authors: T.B. Powles, E. Kopyltsov, P-J. Su, F.X. Parnis, S.H. Park, Y. Yamamoto, P.C. Fong, C. Tournigand, M.A. Climent Duran, A. Bamias, C. Caserta, J. Chang, E. Yan, A. di Pietro, J. Wang, P. Grivas
Journal: Annals of Oncology (2020)
869P Prognostic impact of HPV ctDNA detection during chemoradiotherapy for cervix carcinoma
Authors: L. Cabel, A. Bernard-Tessier, C. Bonneau, C. Tran-Perennou, G. Bataillon, J-G. Féron, V. Fourchotte, R. Rouzier, J-Y. Pierga, N. Scher, M. Minsat, I. Bieche, C. Proudhon, F.C. Bidard, E. Jeannot
Journal: Annals of Oncology (2020)
1262P Randomized, open-label phase III study of pembrolizumab (pembro) vs docetaxel (doce) in patients (pts) with previously treated NSCLC with PD-L1 tumour proportion score (TPS) ≥1%: KEYNOTE-033
Authors: C. Zhou, J. Feng, S. Ma, H. Chen, Z. Ma, C. Huang, L. Zhang, J. He, C. Wang, J. Zhou, P. Danchaivijtr, H-C. Huang, I.O. Vynnychenko, K. Wang, F. Orlandi, V. Sriuranpong, B. Li, J. Ge, T. Dang
Journal: Annals of Oncology (2020)

In KEYNOTE-010, pembro improved OS vs doce as 2L+ therapy for advanced NSCLC with PD-L1 TPS ≥1% and ≥50%. KEYNOTE-010 did not enroll any pts from mainland China, which has high NSCLC mortality. KEYNOTE-033 (NCT02864394) evaluates pembro vs doce in pts with previously treated advanced NSCLC with PD-L1 TPS ≥1%, with most pts enrolled in mainland China. Eligible pts (≥18 y) were randomized to pembro 2 mg/kg Q3W (35 cycles) or doce 75 mg/m2 Q3W (per local standard of care), stratified by TPS (≥50% vs 1–49%). Response was assessed Q9W per RECIST v1.1 by BICR. PD-L1 expression was assessed centrally (PD-L1 IHC 22C3 pharmDx assay). OS and PFS (primary objectives) were evaluated sequentially using stratified log-rank tests, first in pts with TPS ≥50% and then in pts with TPS ≥1% (1-sided α=0.025). 425 pts were enrolled. At data cutoff (Sep 9, 2019), median follow-up was 18.8 (range, 0.2-38.8) mo, and 291 (68%) pts had died. Pembro numerically improved OS in all groups analyzed, but did not achieve predefined statistical significance in pts with PD-L1 TPS ≥50% (Table); thus, sequential testing of OS and PFS ceased. HR for OS in TPS ≥1% pts from mainland China (n=311) was 0.68 (95% CI, 0.51–0.89). In all treated pts, incidence of treatment-related AEs was lower with pembro vs doce (any grade, 70% vs 88%; grade 3-5, 11% vs 47%).Table:PembroDocePD-L1 TPS ≥50%N=114N=113OSMedian (95% CI), mo12.3 (10.0-16.3)10.9 (8.3-13.1)HR (95% CI)0.83 (0.61-1.14)P0.1276PFSMedian (95% CI), mo4.0 (2.1-8.0)2.5 (2.1-4.2)HR (95% CI)0.76 (0.54-1.07)ORR% (95% CI)28.1 (20.1-37.3)7.1 (3.1-13.5)PD-L1 TPS ≥1%N=213N=212OSMedian (95% CI), mo12.9 (10.3-16.5)10.6 (8.7-12.5)HR (95% CI)0.75 (0.60-0.95)PFSMedian (95% CI), mo3.3 (2.1-4.1)3.0 (2.3-4.0)HR (95% CI)0.84 (0.66-1.08)ORR% (95% CI)20.7 (15.4-26.7)5.7 (3.0-9.7) Open table in a new tab While pembro did not meet statistical significance for OS in pts with PD-L1 TPS ≥50%, HRs for OS and PFS numerically favored pembro and ORR was higher with pembro in both the PD-L1 TPS ≥50% and ≥1% groups. Toxicity was consistent with the established pembro safety profile. These data support the value of pembro for previously treated advanced NSCLC in China.
1364P Treatment and outcome of a real-world cohort of patients with advanced, non-squamous NSCLC and KRAS mutations with a special focus on KRAS G12C
Authors: F. Griesinger, W.E.E. Eberhardt, P. Hoffknecht, M. Metzenmacher, T. Wehler, K. Kokowski, J. Alt, W. Schütte, M. Jänicke, A. Fleitz, S. Zacharias, A. Hipper, M. Buller, W. Weichert, M. Groschek, E. von der Heyde, J. Rauh, T. Dechow, M. Sebastian, M. Thomas
Journal: Annals of Oncology (2020)
602TiP A first-in-human study of NOV1601 (CHC2014), small-molecule inhibitor of TRK family proteins, in adult patients with solid organ malignancies
Authors: T. Yun, Y.W. Moon, S.J. Shin, D-W. Kim, C.H. Yun, J.Y. You, B. Hyun, H.W. Cho, J.S. Kim, G. Im, Y. Kim, N. Park
Journal: Annals of Oncology (2020)
Self‐Propelled Micro/Nanomotors for Tumor Targeting Delivery and Therapy
Authors: Ruyi Lin, Wenqi Yu, Xianchun Chen, Huile Gao
Journal: Advanced Healthcare Materials (2020)

Abstract Cancer is still one of the most serious diseases with threats to health and life. Although some advances have been made in targeting delivery of antitumor drugs over the past number of years, there are still many problems needing to be solved, such as poor efficacy and high systemic toxicity. Micro/nanomotors capable of self‐propulsion in fluid provide promising platforms for improving the efficiency of tumor delivery. Herein, the recent progress in micro/nanomotors for tumor targeting delivery and therapy is reviewed, with special focus on the contributions of micro/nanomotors to the different stages of tumor targeting delivery as well as the combination therapy by micro/nanomotors. The present limitations and future directions are also put forward for further development.
1975P Artificial Intelligence-based tool to generate directional integrative treatment reports for cancer patients (ZIOPAR: ZenOnco.io Integrative Oncology Preliminary Assessment Report)
Authors: K. Shah, D. Parmar
Journal: Annals of Oncology (2020)

Journal of Global Oncology (ASCO) published that the new patients per oncologist ratio ranges from 30 to 15,000 across different countries, with only 24% countries having the ratio below 150. This can result in a low quality of care for many cancer patients. Also, South Asian Journal of Cancer published that 85% cancer patients prefer to know the possible treatment options. ZIOPAR provides Artificial Intelligence-based assessment reports free of cost to cancer patients to guide them on possible treatment options, covering both medical as well as complementary approaches. Our team has developed an Artificial Intelligence-based program based on standard protocols, guidelines and research by ESMO, NCCN, ASCO, SIO, others. Cancer patients are required to provide below six basic inputs that determine the output of the report: ► Cancer type / organ site. ► Cancer stage. ► Prior treatment taken (surgery, chemotherapy, radiation therapy). ► Performance status (based on activities that can be performed). ► Symptoms and side-effects (eg, pain, nausea, anxiety). ► Other medical conditions (eg, thyroid, diabetes, liver cirrhosis) Based on these inputs, a report is generated that outlines medical treatment options, diagnostic tests required, and complementary treatment approaches (including guidelines on nutrition, fitness, stress-management, symptom management). Operationally, ZIOPAR captures patient data through an online form, which is transferred to an application that uses Artificial Intelligence to send optimized reports for each patient individually based on specific inputs shared by the patient. The report is shared through email in pdf form to enhance security. ZIOPAR has already benefitted 21,000+ cancer patients and caregivers across 16 countries through its detailed Artificial Intelligence-based preliminary assessment report. ZIOPAR can help millions of cancer patients by providing them an integrative oncology preliminary assessment report containing crucial information to help them decide their treatment option, covering both medical as well as complementary approaches.
1569P Integrating patients’ quality of life (QoL) into clinical practice: A Delphi method-based consensus among French physicians managing lung cancer patients
Authors: V. Westeel, M. Bourdon, A.B. Cortot, D. Debieuvre, A.C. Toffart, M. Acquadro, B. Arnould, J. Lambert, F-E. Cotte, A-F. Gaudin, H. Lemasson
Journal: Annals of Oncology (2020)
1345P Preliminary safety and activity of CLN-081 in NSCLC with EGFR exon 20 insertion mutations (Ins20)
Authors: Z. Piotrowska, D. Nguyen, M. Koczywas, N. Tchekmedyian, M.S. Clancy, D. Witter, A. Page, L. Zawel, H.A. Yu
Journal: Annals of Oncology (2020)
Reply to Lipworth <i>et al.</i>: Don’t Forget about Facilitatory Effects of Corticosteroids on β<sub>2</sub>-Adrenoceptors in Acute Asthma
Authors: Angela M. Moran, Sanjay Ramakrishnan, Catherine A. Borg, Clare M. Connolly, Simon Couillard, Christine M. Mwasuku, Ian D. Pavord, Timothy S. C. Hinks, Lauri Lehtimӓki
Journal: American Journal of Respiratory and Critical Care Medicine (2020)
70P Genomic landscape and efficacy of precision medicine in biliary tract cancers
Authors: A. Hollebecque, L. Tselikas, M.P. Ducreux, A. Boileve, M. Gelli, V. Boige, C. Smolenschi, A. Perret, L. Verlingue, P. Martin-Romano, C. Massard, D. Malka
Journal: Annals of Oncology (2020)
Erratum: Functional Rescue of Dystrophin-Deficient mdx Mice by a Chimeric Peptide-PMO (Functional Rescue of Dystrophin-deficient mdx Mice by a Chimeric Peptide-PMO (2010) 18(10) (1822–1829), (S1525001616308668), (10.1038/mt.2010.151))
Authors: H F Yin, H M Moulton, C Betts, T Merritt, Y Seow, S Ashraf, Q S Wang, J Boutilier, Wood Mja.
Journal: Molecular Therapy (2020)
932P Impact of geriatric assessment on the management of older head and neck cancer patients
Authors: M. Plana, M. Taberna, S. Llop, M. Honorato, E. Vilajosana, I. Linares, O. Bermejo, L. Arribas, A. Lozano, J. Nogués, R. Mesía, M. Antonio
Journal: Annals of Oncology (2020)
511P Real-world survival outcomes of Asian metastatic colorectal cancer patients undergoing hepatectomy from the AsianmCRCRegistry
Authors: C. Teh, S. Cai, J-K. Lin, Y.S. Park, T.W. Kim, E. Sirachainan, B. Ma, J-Y. Wang, W.T-L. Chen, H-M. Wang, C-C. Chen, J.Y. Baek, S. Zhang, S.S. P, J. Xu, S. Shrikhande, J-C. Lee, B. Jia, Y-L. He, J. Huang
Journal: Annals of Oncology (2020)
543P Entrectinib in NTRK fusion-positive NSCLC: Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Authors: A. Drilon, L. Paz-Ares, R.C. Doebele, A.F. Farago, S.V. Liu, S.P. Chawla, D. Tosi, C.M. Blakely, J.C. Krauss, L. Bazhenova, T. John, B. Besse, J. Wolf, T. Seto, B.C. Cho, C. Rolfo, S. Osborne, A. Aziez, G.D. Demetri
Journal: Annals of Oncology (2020)
1713P Active smoking and severity of COVID-19 infection in cancer patients
Authors: G.D.H. Marta, E. Auclin, N. Saoudi Gonzalez, D. Casadevall Aguilar, M. Rodriguez Castells, N. Epaillard, M. Tagliamento, S. Pilotto, R. López-Castro, X. Mielgo Rubio, C. Urbano Centella, E. Pineda, F.M. Laia, O. Mirallas, M.V. Bluthgen, L. Masfarré, J.N. Minatta, C.A. Cruz, A. Prat, L. Mezquita
Journal: Annals of Oncology (2020)
985P A phase II study of camrelizumab for advanced hepatocellular carcinoma: Two-year outcomes and continued treatment beyond RECIST-defined progression
Authors: Z. Ren, S. Qin, Z. Meng, Z. Chen, X. Chai, J. Xiong, Y. Bai, L. Yang, H. Zhu, W. Fang, X. Lin, X. Chen, E. Li, L. Wang, C. Chen, J. Zou
Journal: Annals of Oncology (2020)
Human Antibodies Targeting Influenza B Virus Neuraminidase Active Site Are Broadly Protective
Authors: Anders Madsen, Ya-Nan Dai, Meagan McMahon, Aaron J. Schmitz, Jackson S. Turner, Jessica Tan, Tingting Lei, Wafaa B. Alsoussi, Shirin Strohmeier, Mostafa Amor, Bassem M. Mohammed, Philip A. Mudd, Viviana Simon, Rebecca J. Cox, Daved H. Fremont, Florian Krammer, Ali H. Ellebedy
Journal: Immunity (2020)
LTP Induction Boosts Glutamate Spillover by Driving Withdrawal of Perisynaptic Astroglia
Authors: Christian Henneberger, Lucie Bard, Aude Panatier, James P. Reynolds, Olga Kopach, Nikolay I. Medvedev, Daniel Minge, Michel K. Herde, Stefanie Anders, Igor Kraev, Janosch P. Heller, Sylvain Rama, Kaiyu Zheng, Thomas P. Jensen, Inmaculada Sanchez-Romero, Colin J. Jackson, Harald Janovjak, Ole Petter Ottersen, Erlend Arnulf Nagelhus, Stephane H.R. Oliet, Michael G. Stewart, U. Valentin Nägerl, Dmitri A. Rusakov
Journal: Neuron (2020)

Extrasynaptic actions of glutamate are limited by high-affinity transporters expressed by perisynaptic astroglial processes (PAPs): this helps maintain point-to-point transmission in excitatory circuits. Memory formation in the brain is associated with synaptic remodeling, but how this affects PAPs and therefore extrasynaptic glutamate actions is poorly understood. Here, we used advanced imaging methods, in situ and in vivo, to find that a classical synaptic memory mechanism, long-term potentiation (LTP), triggers withdrawal of PAPs from potentiated synapses. Optical glutamate sensors combined with patch-clamp and 3D molecular localization reveal that LTP induction thus prompts spatial retreat of astroglial glutamate transporters, boosting glutamate spillover and NMDA-receptor-mediated inter-synaptic cross-talk. The LTP-triggered PAP withdrawal involves NKCC1 transporters and the actin-controlling protein cofilin but does not depend on major Ca
104P Angiogenesis-related factors and clinical outcomes in combination therapy with paclitaxel (PTX), ramucirumab (RAM) plus nivolumab (Nivo) for advanced gastric cancer (AGC)
Authors: N. Izawa, S. Ohta, S. Kadowaki, T. Kajiwara, K. Minashi, Y. Sunakawa, K. Muro, T. Nishina, S. Hironaka, T. Yamanaka, T.E. Nakajima, Y. Kawakami
Journal: Annals of Oncology (2020)
1131P C-reactive protein as biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting
Authors: J. Lauwyck, A. Beckwée, A. Santens, J.K. Schwarze, G. Awada, V. Vandersleyen, S. Aspeslagh, B. Neyns
Journal: Annals of Oncology (2020)
Birnie Winchester Duthie
Authors: Elaine MacEachern
Journal: BMJ (2020)

Birnie Winchester Duthie was born in Rosehearty on 12 August 1928 and died from Parkinson’s disease and heart disease on 8 February 2020. He lived at Angusfield House Care Home, Aberdeen, for the last four years of his life along with his wife, Ella, who lived there in the dementia unit for seven years. Ella died from Alzheimer’s disease on 29 May 2020.

Birnie attended Fraserburgh Academy, and war was declared two or three weeks after he started there in the summer of 1939. He started his medical degree at Aberdeen University in 1944. As well as studying …
723P Response to systemic therapy in fumarate hydratase (FH) mutated papillary renal cell carcinoma (pRCC): Is there a winner?
Authors: L. Carril, E. Colomba-Blameble, L. Cerbone, L. Crouzet, B. Laguerre, C. Thibault, C. Vicier, G. de Velasco, A. Fléchon, C. Saldana, S. Richard, O. Caron, B. Escudier, L. Albiges
Journal: Annals of Oncology (2020)
54P Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/other rearrangements: Subgroup analyses of a phase II study (FOENIX-CCA2)
Authors: J. Bridgewater, F. Meric-Bernstam, A. Hollebecque, J.W. Valle, C. Morizane, T. Karasic, T. Abrams, J. Furuse, R.K. Kelley, P. Cassier, H-J. Klümpen, N. Uboha, A. Mahipal, E. Mitchell, E.R. Ahn, H-M. Chang, K. Masuda, Y. He, K. Benhadji, L. Goyal
Journal: Annals of Oncology (2020)
LBA11 IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab + chemotherapy in early triple-negative breast cancer (TNBC)
Authors: N. Harbeck, H. Zhang, C.H. Barrios, S. Saji, K.H. Jung, R. Hegg, A. Koehler, J. Sohn, H. Iwata, M.L. Telli, C. Ferrario, K. Punie, F. Penault-Llorca, S. Patel, A. Nguyen Duc, M. Liste-Hermoso, V. Maiya, L. Molinero, S.Y. Chui, E. Mittendorf
Journal: Annals of Oncology (2020)
A novel technique for mapping biopsy of bile duct cancer
Authors: Hirokazu Okada, Norimitsu Uza, Tomoaki Matsumori, Shimpei Matsumoto, Yuya Muramoto, Sakiko Ota, Takeharu Nakamura, Hiroyuki Yoshida, Tomonori Hirano, Takeshi Kuwada, Saiko Marui, Yuko Sogabe, Toshihiro Morita, Nobuyuki Kakiuchi, Atsushi Mima, Tatsuki Ueda, Yoshihiro Nishikawa, Motoyuki Tsuda, Takahisa Maruno, Masahiro Shiokawa, Ken Takahashi, Kojiro Taura, Sachiko Minamiguchi, Yuzo Kodama, Hiroshi Seno
Journal: Endoscopy (2020)

Abstract Background Accurate preoperative assessment of the longitudinal extension of perihilar cholangiocarcinoma (PHCC) is essential for treatment planning. Mapping biopsies for PHCC remain challenging owing to technical difficulties and insufficient sample amounts. The aim of this study was to investigate the usefulness of a novel technique for mapping biopsies of PHCC. Methods Our novel method focused on a biliary stent delivery system for mapping biopsies. Fifty patients with PHCC undergoing endoscopic transpapillary mapping biopsy using the novel method were reviewed from August 2015 to June 2019. Results The median number of biopsy samples was six (range 1 – 17), and the rate of adequate sampling was 91.4 % (266 /291). Biopsy from the intrahepatic bile duct was possible in 82.0 % of patients (41 /50), and negative margins were confirmed in the resected specimens from 34 /39 patients who underwent surgery (87.2 %). None of the patients had post-endoscopic retrograde cholangiopancreatography pancreatitis. Conclusions With our novel method, accurate assessment of the longitudinal extension of PHCC might be expected with minimal trauma to the duodenal papilla.
790P Palliative chemotherapy in patients with advanced nonseminomatous germ cell tumors (aNSGCT)
Authors: A. Tryakin, M. Fedyanin, A. Bulanov, A. Rumyantsev, Y. Sergeev, G. Petrova, V. Matveev, M. Volkova, A. Klimov, I. Fainstein, B. Akhmedov, I. Kurmukov, A.M. Garin, S. Tjulandin
Journal: Annals of Oncology (2020)
Interactions Between Genome‐Wide Genetic Factors and Smoking Influencing Risk of Systemic Lupus Erythematosus
Authors: Jing Cui, Soumya Raychaudhuri, Elizabeth W. Karlson, Cameron Speyer, Susan Malspeis, Hongshu Guan, Jeffrey A. Sparks, Hongru Ni, Xinyi Liu, Emma Stevens, Jessica N. Williams, Emma E. Davenport, Rachel Knevel, Karen H. Costenbader
Journal: Arthritis & Rheumatology (2020)

To identify interactions between genetic factors and current or recent smoking in relation to risk of developing systemic lupus erythematosus (SLE).For the study, 673 patients with SLE (diagnosed according to the American College of Rheumatology 1997 updated classification criteria) were matched by age, sex, and race (first 3 genetic principal components) to 3,272 control subjects without a history of connective tissue disease. Smoking status was classified as current smoking/having recently quit smoking within 4 years before diagnosis (or matched index date for controls) versus distant past/never smoking. In total, 86 single-nucleotide polymorphisms and 10 classic HLA alleles previously associated with SLE were included in a weighted genetic risk score (wGRS), with scores dichotomized as either low or high based on the median value in control subjects (low wGRS being defined as less than or equal to the control median; high wGRS being defined as greater than the control median). Conditional logistic regression models were used to estimate both the risk of SLE and risk of anti-double-stranded DNA autoantibody-positive (dsDNA+) SLE. Additive interactions were assessed using the attributable proportion (AP) due to interaction, and multiplicative interactions were assessed using a chi-square test (with 1 degree of freedom) for the wGRS and for individual risk alleles. Separate repeated analyses were carried out among subjects of European ancestry only.The mean ± SD age of the SLE patients at the time of diagnosis was 36.4 ± 15.3 years. Among the 673 SLE patients included, 92.3% were female and 59.3% were dsDNA+. Ethnic distributions were as follows: 75.6% of European ancestry, 4.5% of Asian ancestry, 11.7% of African ancestry, and 8.2% classified as other ancestry. A high wGRS (odds ratio [OR] 2.0, P = 1.0 × 10-51 versus low wGRS) and a status of current/recent smoking (OR 1.5, P = 0.0003 versus distant past/never smoking) were strongly associated with SLE risk, with significant additive interaction (AP 0.33, P = 0.0012), and associations with the risk of anti-dsDNA+ SLE were even stronger. No significant multiplicative interactions with the total wGRS (P = 0.58) or with the HLA-only wGRS (P = 0.06) were found. Findings were similar in analyses restricted to only subjects of European ancestry.The strong additive interaction between an updated SLE genetic risk score and current/recent smoking suggests that smoking may influence specific genes in the pathogenesis of SLE.
Tafazzin (TAZ) Regulates the Differentiation of AML Cells By Reducing Levels of the Phospholipid Phosphatidylethanolamine
Authors: Ayesh K Seneviratne, Juan J Aristizabal Henao, G Wei Xu, Rose Hurren, Sejin Kim, Neil MacLean, Xioaming Wang, Mingjing Xu, Val Fajado, Zhenyue Hao, Marcela Gronda, Danny V. Jeyaraju, Raphael Chouinard-Watkins, Caitlin Schafer, Paul LeBlanc, Khuchua Zaza, Richard Bazinet, Steven Claypool, Ken Stark, Aaron Schimmer
Journal: Blood (2017)
1475P Negative impact of intraoperative blood loss on long-term outcome after curative gastrectomy for cT3/4a gastric cancer - Exploratory analysis of JCOG1001 study
Authors: K. Misawa, Y. Kurokawa, J. Mizusawa, S. Takiguchi, Y. Doki, S. Makino, Y. Choda, A. Takeno, M. Tokunaga, T. Sano, M. Sasako, T. Yoshikawa, M. Terashima
Journal: Annals of Oncology (2020)
1234TiP SYMptom monitoring with patient-reported outcomes using a web application among lung cancer patients in the Netherlands (SYMPRO-Lung)
Authors: N.E. Billingy, E. Veldhuijzen, V. Tromp, J. Belderbos, N. Aaronson, H.J. Bogaard, E. Feldman, R. Hoek, B. Onwuteaka-Philipsen, L. van de Poll-Franse, J. Hugtenburg, I. Walraven, C. van den Hurk, A. Becker
Journal: Annals of Oncology (2020)
265P Circulating PIK3CA mutation detection at diagnosis in non-metastatic inflammatory breast cancer patients
Authors: V. Allouchery, A. Perdrix, C. Calbrix, A. Berghian, J. Lequesne, M. Fontanilles, M. Leheurteur, P. Etancelin, N. Sarafan Vasseur, F. Di Fiore, F. Clatot
Journal: Annals of Oncology (2020)
792P A retrospective review of the survival outcomes of patients with nonseminomatous germ cell tumors (NSGCTs) with and without teratoma in the primary
Authors: M. Pedregal Trujillo, P.K. Ravi, G.K. Shaw, S.C. Markt, A. Hamid, A. Tewari, E.M. Van Allen, C. Sweeney
Journal: Annals of Oncology (2020)
1276P Nivolumab treatment in advanced non-small cell lung cancer (aNSCLC): Real-world 3-year outcomes within overall and special populations (the UNIVOC study)
Authors: J-B. Assié, R. Corre, M. Giaj Levra, C.Y. Calvet, V. Grumberg, A-F. Gaudin, B. Jouaneton, F-E. Cotté, C. Chouaid
Journal: Annals of Oncology (2020)
2014TiP REBIMMUNE trial: A prospective study of REBiopsy at progression during IMMUNothErapy in advanced lung cancer
Authors: E. Giroux-Leprieur, A. Costantini, C. Julie, P. Takam Kamga, F. Parent, A. Seferian, C. Dumenil, J. Dumoulin, V. Giraud, J. Ouaknine, A. Lemoine, M. Humbert, T. Chinet, J.F. Emile
Journal: Annals of Oncology (2020)